Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Uniqure Ord Shs (NQ: QURE )

5.990 +0.210 (+3.63%)
Streaming Delayed Price Updated: 3:57 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Uniqure Ord Shs

< Previous 1 2 3 4 5 6 Next >
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
~ Walid Abi-Saab, M.D., appointed Chief Medical Officer, will bring extensive track record in leading drug development and execution ~ 
From uniQure Inc.
Via GlobeNewswire
Why uniQure Stock Cratered This Week
An interim analysis for the company's Huntington's disease gene therapy wasn't a hit with investors. 
Via The Motley Fool
Chardan Capital Maintains Buy Rating for uniQure: Here's What You Need To Know
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why UniQure Stock Is Trading Down Today
UniQure N.V. (NASDAQ: QURE) shares are lower after the company announced interim data from the Phase I/II trial of AMT-130 in Huntington's Disease. 
Via Benzinga
Where uniQure Stands With Analysts
Via Benzinga
Nordson To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Thursday
Chardan Capital cut the price target for uniQure N.V. (NASDAQ: QURE) from $45 to $27. Chardan Capital analyst Matthew Barcus maintained a Buy rating. uniQure shares fell 1.5% to $11.45 in pre-market... 
Via Benzinga
Crude Oil Rises 2%; LumiraDx Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded down 0.04% to 34,040.13 while the NASDAQ fell 0.77% to 13,562.00. The S&P... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why uniQure Stock Is Crashing Today
Investors are focusing on the negative parts of the biotech company's interim results. 
Via The Motley Fool
6 Analysts Have This to Say About uniQure
Via Benzinga
Analyst Ratings for uniQure
Via Benzinga
Why ToughBuilt Industries Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 209.5% to $2.29 after the company signed a Letter of Intention with UAE-Based e-script medicine management company Pharmak... 
Via Benzinga
Nasdaq Tumbles 1%; Patterson Companies Earnings Beat Views
U.S. stocks traded mostly lower midway through trading, with Nasdaq Composite dropping over 100 points on Wednesday. 
Via Benzinga
Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene Therapy
The company is working on a one-time treatment for Huntington's disease. 
Via Investor's Business Daily
Dow Drops Over 100 Points; Winnebago Industries Posts Downbeat Sales
U.S. stocks traded lower this morning, with Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.41% to 33,914.60 while the NASDAQ fell 0.31%... 
Via Benzinga
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring 
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
uniQure's Hemgenix Royalty Sales Agreement Extends Cash Runway, Relieves Near-Term Commercial Risk, Says Analyst
uniQure N.V. (NASDAQ: QURE) agreed to sell a portion of the royalty rights due from CSL Behring from Hemgenix (etranacogene dezaparvovec-drbl) net sales to HealthCare Royalty and Sagard Healthcare  
Via Benzinga
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
From uniQure Inc.
Via GlobeNewswire
Recap: uniQure Q1 Earnings
uniQure (NASDAQ:QURE) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:05 AM. Here's what investors need to know about the announcement. Earnings uniQure missed estimated earnings by... 
Via Benzinga
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
uniQure to Participate in Multiple Upcoming Industry Conferences in March
From uniQure Inc.
Via GlobeNewswire
uniQure Stock Trying To Close In On Key Technical Measure
uniQure stock had its Relative Strength Rating upgraded to 79 Tuesday -- a nice improvement, but still shy of the 80-plus desired score. 
Via Investor's Business Daily
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.